NATCO documents typical Olaparib Tablets in USA by admin- Monday, February 13th, 2023 03:45:05 PM
NATCO Pharma introduced submission of Abbreviated New Drug Application (ANDA) containing a paragraph IV certification with america Food and Drug Administration (FDA) for the well-known version of Olaparib Tablets 100mg and 150mg.
Olaparib is indicated generally for sure kinds of ovarian, breast, pancreatic and prostrate most cancers. Olaparib Tablets are marketed inside the United States (US) by using AstraZeneca below logo Lynparza. NATCO has been named as defendant in a lawsuit filed in the US district court of New Jersey by AstraZeneca and Kudos Pharmaceuticals.
NATCO and its co-improvement and advertising accomplice Alembic Pharmaceuticals consider that the ANDA is possibly sole first-to-record based on its filing date and may be eligible for 180 days of advertising and marketing exclusivity on the time of release of the product.